http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-037062-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7021163b729521289028313faa08a079 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate | 1999-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7964258179497db7c8895bf2338d153 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_726dcccf3378fb8983b72d681b5a97f0 |
| publicationDate | 2004-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-037062-A1 |
| titleOfInvention | ADJUSED DNA VACCINE AND USE OF AN ELECTED COMPOUND BETWEEN ACRYLIC OR METACRYLIC ACID POLYMERS AND MALEIC ANHYDRIDE AND ALQUENILE DERIVATIVE COPOLYMERS TO ADJUDE SUCH DNA VACCINE |
| abstract | Claim 1: DNA vaccine comprising a naked DNA that incorporates and expresses in vivo a nucleotide sequence encoding an antigenic polypeptide, preferably a gene of a pathogen, and at least one adjuvant compound chosen from acrylic or methacrylic polymers and copolymers of maleic anhydride and alkenyl derivative. Claim 2: Vaccine according to claim 1, characterized in that it comprises as an adjuvant compound an acrylic or methacrylic acid polymer crosslinked by a polyalkenyl sugar or polyalcohol ether Claim 3: Vaccine according to claim 2, characterized in that the polymer is crosslinked by an alilsacarose or alilpentaerythritol. Claim 5: Vaccine according to any of claims 1 to 4, interchangeably, characterized in that the adjuvant compound is present in the vaccine at a rate of 0.01% to 2% P / V. Claim 7: Vaccine according to any one of claims 1 to 6, interchangeably, characterized in that the naked DNA is a plasmid Claim 9: Vaccine according to claim 8, characterized in that it comprises at least one sequence of a pathogen chosen from: virus of the Aujeszky's disease, swine flu virus, mysterious pig disease virus, swine parvovirosis virus, classical swine fever virus, Actinobacilus pleuropneumoniae, equine rhinopneumonia virus, equine flu virus, Cl. tetani, Eastern encephalitis virus, western encephalitis virus, Venezuelan encephalitis virus, B. burgdorferi, Carré disease virus, canine parvovirus, canine coronavirus, canine herpes virus, rabies virus, bovine herpes virus type 1 or 5, bovine syncytial respiratory virus, bovine pestivirus, bovine parainfluenza virus type 3, feline leukemia virus, feline panleukopenia virus, vir us of feline infectious peritonitis, feline herpevirus, feline calicivirosis virus, feline immunodeficiency virus, Marek's disease virus, Newcastle disease virus, Gumboro disease virus, infectious bronchitis virus birds, infectious bird anemia virus, infectious laryngotracheitis virus, bird leukosis virus, bird pneumovirus, bird plague virus. |
| priorityDate | 1998-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 29.